6C8488D3-6826-4156-9BD9-A12D8F35B72B
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.443
- TNFA_SIGNALING_VIA_NFKB+0.439
- NOTCH_SIGNALING+0.432
- PROTEIN_SECRETION+0.391
- CHOLESTEROL_HOMEOSTASIS+0.338
- INTERFERON_ALPHA_RESPONSE+0.324
- APOPTOSIS+0.311
- ANDROGEN_RESPONSE+0.291
- FATTY_ACID_METABOLISM+0.285
- INTERFERON_GAMMA_RESPONSE+0.275
Top 10 suppressed
- SPERMATOGENESIS-0.258
- PANCREAS_BETA_CELLS-0.205
- E2F_TARGETS-0.190
- KRAS_SIGNALING_DN-0.155
- G2M_CHECKPOINT-0.150
- DNA_REPAIR-0.129
- MYC_TARGETS_V2-0.120
- MYC_TARGETS_V1-0.097
- HEDGEHOG_SIGNALING-0.055
- OXIDATIVE_PHOSPHORYLATION-0.027
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 9A593453-3B4C-4557-84BF-E9E902AA0F3F | — | — | 0.931 |
| 2 | 0F8847C7-545C-4C3C-B3D0-0681C9480712 | — | — | 0.903 |
| 3 | SRR934843 | — | — | 0.896 |
| 4 | SRR934729 | — | — | 0.889 |
| 5 | 31D3488A-212B-4818-8F09-EBF1E8B135AD | — | — | 0.856 |
| 6 | DACCA07A-8F2C-40C5-B8AD-73805E408D85 | — | — | 0.847 |
| 7 | BS_J4GQPZS0 | Schwannoma | — | 0.845 |
| 8 | SRR1458595 | GTEX | — | 0.843 |
| 9 | SRR660895 | GTEX | — | 0.842 |
| 10 | 01B819BD-664B-4D9E-B60B-9D9E8305A626 | — | — | 0.841 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.443 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.439 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.432 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.391 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.338 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.324 | Inavolisib | — uncovered |
| APOPTOSIS | 0.311 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.291 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.285 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.275 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.274 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.248 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.247 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.230 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.226 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.218 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.204 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.204 | Temsirolimus | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.190 | Inavolisib | — uncovered |
| COMPLEMENT | 0.189 | Inavolisib | — uncovered |